Entod Pharma Gets CDSCO Approval for Eye Drop to Slow Myopia in Children

Entod Pharmaceuticals, a global research-driven ophthalmic company, announced that it has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for a new eye formulation developed to slow the progression of myopia in children aged 6 to 12 years. This marks the first global regulatory approval for this unique treatment strength of an eye medicine specifically for paediatric use.
 
This milestone follows the successful completion of phase 3 clinical trials in  India and a rigorous approval process by India’s apex drug regulator. The treatment will be available strictly by prescription from a registered medical practitioner for children diagnosed with myopia, following an evaluation by an eye doctor.
 
Dr. Mohita Sharma, medical director at Tirupati Eye Centre & Research Institute and a principal investigator in the Indian clinical study, commented, ""Myopia, or near sightedness, is a growing public health concern, especially among school-aged children with increased exposure to prolonged near work and digital screens. This new treatment is a significant advancement in paediatric eye care, offering a means to effectively slow the progression of myopia after detailed examination to determine the child's suitability for this treatment, and to help prevent complications associated with high myopia and improve long-term visual outcomes.""
 
Commenting on the CDSCO’s marketing approval, Nikkhil K Masurkar, CEO of Entod Pharmaceuticals, stated, ""This is a proud moment for our research and regulatory teams. Securing regulatory approval for this unique treatment strength—the first of its kind globally—underscores our continued commitment to innovation in eye care. With myopia rates in India rising from 4% in 1999 to nearly 25% today, and projections suggesting that by 2050 one in two children could be affected, the need for such a therapy has never been more urgent.""
 
Entod Pharmaceuticals is a global research-driven ophthalmic company with over 47 years of experience developing innovative eye care solutions. With a presence in more than 67 countries, Entod continues to advance its ""Make in India for the World"" mission by delivering accessible, affordable, and world-class eye treatments.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!